Canadian Reimbursement and Forecasting Timelines (CRaFT) Report
PRE-ORDER NOW
2022 Edition of CRaFT Report and NEW Drugs for Rare Disease (DRD) Sub-Report
MORSE Consulting will be releasing its 2022 edition of the Canadian Reimbursement and Forecasting Timelines (CRaFT) report and a NEW Drugs for Rare Disease (DRD) sub-report in April. MORSE analyzed Canadian market access data from the past several years to develop key reimbursement metrics and insights to help pharmaceutical companies with their forecasting or planning needs.
- CRaFT 2022 edition is a 100+ page PowerPoint report with data analytics and reimbursement trends for oncology, non-oncology, and biosimilar products from 2018-2021.
- *NEW* The DRD sub-report is a 30+ page PowerPoint addendum, only available for purchase by CRaFT 2022 edition subscribers, which provides insights into trends related to DRDs from 2017-2021. Â
- Both reports include detailed analysis and payer insights on the entire reimbursement process from CADTH to pCPA and jurisdictional listing.
Together, these reports are a comprehensive source of reimbursement timeline information to assist companies with their upcoming Canadian launch.
For further information on content and pricing, please complete the form below.
This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.
We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.
